Avicanna Inc (AVCN) - Total Liabilities
Based on the latest financial reports, Avicanna Inc (AVCN) has total liabilities worth CA$9.29 Million CAD (≈ $6.72 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Avicanna Inc to track the company's year-over-year net asset growth rate.
Avicanna Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Avicanna Inc's total liabilities have evolved over time, based on quarterly financial data. See AVCN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Avicanna Inc Competitors by Total Liabilities
The table below lists competitors of Avicanna Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daewoo SBI SPAC 1
KQ:215480
|
Korea | ₩8.09 Billion |
|
Ata Gayrimenkul Yatirim Ortakligi AS
IS:ATAGY
|
Turkey | TL177.43 Million |
|
Spire Healthcare Group Plc
LSE:SPI
|
UK | GBX1.63 Billion |
|
LX Hausys Ltd Preferred
KO:108675
|
Korea | ₩1.35 Trillion |
|
Wooree Lighting Co.Ltd
KQ:037400
|
Korea | ₩548.02 Billion |
|
Activeport Group Ltd
AU:ATV
|
Australia | AU$5.57 Million |
|
Daedong Metals Co. Ltd
KQ:020400
|
Korea | ₩55.28 Billion |
|
Armlogi Holding Corp. Common Stock
NASDAQ:BTOC
|
USA | $130.28 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Avicanna Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Avicanna Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avicanna Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avicanna Inc (2016–2025)
The table below shows the annual total liabilities of Avicanna Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$9.86 Million ≈ $7.13 Million |
-5.00% |
| 2024-12-31 | CA$10.38 Million ≈ $7.51 Million |
-25.89% |
| 2023-12-31 | CA$14.00 Million ≈ $10.13 Million |
-1.14% |
| 2022-12-31 | CA$14.16 Million ≈ $10.24 Million |
-8.01% |
| 2021-12-31 | CA$15.39 Million ≈ $11.14 Million |
-5.25% |
| 2020-12-31 | CA$16.25 Million ≈ $11.75 Million |
+6.26% |
| 2019-12-31 | CA$15.29 Million ≈ $11.06 Million |
+748.74% |
| 2018-12-31 | CA$1.80 Million ≈ $1.30 Million |
+41.13% |
| 2017-12-31 | CA$1.28 Million ≈ $923.33K |
+939.73% |
| 2016-12-31 | CA$122.76K ≈ $88.80K |
-- |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more